Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Asher · SciRah

Researcher profile · Semantic Scholar

N. Asher

Share profile

N. Asher — researcher profile on SciRah

h-index: 16
Works: 52
Citations: 2,223

Most-cited papers

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
E. Baruch, I. Youngster, Guy Ben-Betzalel, R. Ortenberg +28 more
2020Science1,516 citations
Semantic Scholar
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
N. Asher, Guy Ben-Betzalel, Shaked Lev-Ari, R. Shapira-Frommer +5 more
2020Cancers64 citations Open access
Semantic Scholar
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
Abraham Nissani, Shaked Lev-Ari, Tomer Meirson, E. Jacoby +7 more
2021Journal for ImmunoTherapy of Cancer63 citations Open access
Semantic Scholar
Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
Guy Ben-Betzalel, Yael Steinberg-Silman, R. Stoff, N. Asher +3 more
2019European Journal of Cancer57 citations
Semantic Scholar
Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
Y. Eshet, E. Baruch, R. Shapira-Frommer, Yael Steinberg-Silman +10 more
2018Cancer immunology research50 citations Open access
Semantic Scholar
Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
N. Asher, E. Marom, Guy Ben-Betzalel, E. Baruch +4 more
2019The Oncologist48 citations Open access
Semantic Scholar
Neoadjuvant BRAF Targeted Therapy for Ameloblastoma of the Mandible: an Organ Preservation Approach.
S. Grynberg, Marilena Vered, R. Shapira-Frommer, N. Asher +12 more
2023Journal of the National Cancer Institute40 citations Open access
Semantic Scholar
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Guy Ben-Betzalel, E. Baruch, B. Boursi, Yael Steinberg-Silman +4 more
2018European Journal of Cancer38 citations
Semantic Scholar
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response
M. Besser, O. Itzhaki, Guy Ben-Betzalel, D. Zippel +13 more
2020Molecular Carcinogenesis35 citations
Semantic Scholar
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
Tomer Meirson, N. Asher, D. Bomze, G. Markel
2020Cancers31 citations Open access
Semantic Scholar
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
D. Bomze, N. Asher, Omar Hasan Ali, L. Flatz +3 more
2020JAMA Network Open31 citations Open access
Semantic Scholar
Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience
N. Asher, Noa Israeli-Weller, R. Shapira-Frommer, Guy Ben-Betzalel +3 more
2021Cancers26 citations Open access
Semantic Scholar
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases e A multicenter cohort study
C. Holmberg, L. Ny, T. Hieken, M. Block +41 more
2022European Journal of Cancer24 citations Open access
Semantic Scholar
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma
Jack Pepys, R. Stoff, Roni Ramon-Gonen, Guy Ben-Betzalel +8 more
2023Neurology21 citations
Semantic Scholar
Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
R. Stoff, S. Grynberg, N. Asher, S. Laks +4 more
2022Frontiers in Oncology17 citations Open access
Semantic Scholar
Abstract CT042: Fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 therapy in refractory metastatic melanoma patients - preliminary results from a phase I clinical trial (NCT03353402)
E. Baruch, I. Youngster, R. Ortenberg, Guy Ben-Betzalel +22 more
2019Clinical Trials17 citations
Semantic Scholar
Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy
Neta Bar-Hai, Guy Ben-Betzalel, R. Stoff, S. Grynberg +3 more
2023Cancers16 citations Open access
Semantic Scholar
Oncologic patients’ misconceptions may impede enrollment into clinical trials: a cross-sectional study
N. Asher, A. Raphael, I. Wolf, Sharon Pelles +1 more
2021BMC Medical Research Methodology16 citations Open access
Semantic Scholar
Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
R. Stoff, N. Asher, S. Laks, Yael Steinberg +4 more
2023Frontiers in Oncology15 citations Open access
Semantic Scholar
Immune checkpoint inhibitors–related encephalitis in melanoma and non-melanoma cancer patients: a single center experience
A. Taliansky, O. Furman, M. Gadot, D. Urban +6 more
2021Supportive Care in Cancer14 citations Open access
Semantic Scholar
Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
I. Averbuch, R. Stoff, M. Miodovnik, S. Fennig +5 more
2023Cancer Medicine13 citations Open access
Semantic Scholar
Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients
S. Grynberg, R. Stoff, N. Asher, R. Shapira-Frommer +4 more
2022Therapeutic Advances in Medical Oncology12 citations Open access
Semantic Scholar
The non-responding adrenal metastasis in melanoma: The case for minimally invasive adrenalectomy in the age of modern therapies.
D. Zippel, T. Yalon, Y. Nevo, G. Markel +6 more
2019American Journal of Surgery10 citations
Semantic Scholar
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases
Danielle K. DePalo, Michelle M. Dugan, S. M. H. Naqvi, D. Ollila +26 more
2024Cancer9 citations Open access
Semantic Scholar
MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2.
E. Markovits, Ortal Harush, E. Baruch, E. Shulman +14 more
2023Cancer immunology research8 citations Open access
Semantic Scholar
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.
M. Weichenthal, E. Ellebaek, J. Mangana, N. Asher +44 more
2025European Journal of Cancer7 citations Open access
Semantic Scholar
Feline cognitive dysfunction as a model for Alzheimer’s disease in the research of CBD as a potential treatment—a narrative review
Lilach Zadik-Weiss, Sivan Ritter, Vered Hermush, N. Asher +2 more
2020Journal of Cannabis Research7 citations Open access
Semantic Scholar
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
P. Grover, I. Li, A. Kuijpers, F. Kreidieh +16 more
2023Journal of Clinical Oncology6 citations
Semantic Scholar
Real‐World Outcomes of Inoperable and Metastatic Cutaneous Head and Neck Melanoma Patients
N. Rozendorn, Itay Shutan, Gilad Feinmesser, S. Grynberg +3 more
2024The Laryngoscope5 citations
Semantic Scholar
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy
N. Asher, Neta Bar-Hai, Guy Ben-Betzalel, R. Stoff +3 more
2024Melanoma research5 citations Open access
Semantic Scholar
Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma: An EUMelaReg real world study.
N. Asher, Peter Mohr, E. Ellebaek, Marc Bender +9 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
A novel deep learning pipeline for cell typing and phenotypic marker quantification in multiplex imaging
E. Markovits, T. Dankovich, Roman Gluskin, Ido D. Weiss +13 more
2022bioRxiv3 citations Open access
Semantic Scholar
Treatment with programmed-death-1 inhibitors for non-melanoma skin cancer among immunocompromised patients with subgroup analysis of solid organ transplant patients
E. Yosefof, N. Edri, Idan Ben-Nachum, D. Yaniv +6 more
2025The Oncologist2 citations Open access
Semantic Scholar
PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy.
E. Mor, G. Schtrechman, E. Nizri, Michal Shimonovitz +14 more
2023European Journal of Surgical Oncology2 citations
Semantic Scholar
PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis
Ido Amir, N. Edri, I. Averbuch, N. Asher +8 more
2026The Oncologist1 citations Open access
Semantic Scholar
Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation
I. Averbuch, N. Edri, N. Asher, G. Markel +4 more
2025Cancer Immunology and Immunotherapy1 citations Open access
Semantic Scholar
Exploring the clinical significance of specific immune-related adverse events (irAE) in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
N. Asher, Neta Bar-Hai, Guy Ben-Betzalel, R. Stoff +3 more
2023Journal of Clinical Oncology1 citations Open access
Semantic Scholar
64 Augmenting low-plex multiplex imaging by leveraging the potential of same-slide H&E analysis
B. Arbiv, A. Debby, N. Asher, Guy Ben-Betzalel +13 more
2023Regular and Young Investigator Award Abstracts1 citations Open access
Semantic Scholar
The increasing role of abdominal metastesectomy for malignant melanoma in the era of modern therapeutics.
E. Mor, S. Laks, D. Assaf, N. Asher +9 more
2022Surgical oncology1 citations
Semantic Scholar
526 Removal of soluble tumor necrosis factors receptors 1/2 in patients with metastatic solid tumors using immune apheresis
A. Tamir, H. Harati, N. Asher, R. Stoff +6 more
2021Journal for ImmunoTherapy of Cancer1 citations Open access
Semantic Scholar
Vulvar and Vaginal Melanoma: Real-world Clinical Outcomes and Prognostic Differences From a Single-center Experience.
N. Asher, S. Grynberg, Jacob Schachter, R. Shapira-Frommer
2026Journal of Lower Genital Tract Disease0 citations
Semantic Scholar
Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma.
N. Asher, Moti Avner, Nadav Goldberg, G. Markel +11 more
2026European Journal of Cancer0 citations
Semantic Scholar
Germline POT1 variants are associated with long telomeres and an unexpected broad spectrum of malignancies
Aasem Abu Shtaya, Shahar Aloni, M. Eskin-Schwartz, N. Asher +28 more
2026Genetics in medicine open0 citations Open access
Semantic Scholar
A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit metastases in a contemporary patient population.
C. Balsay-Patel, Michelle M. Dugan, S. Naqvi, D. Ollila +16 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Extracorporeal removal of soluble tumor necrosis factor receptors for the treatment of advanced refractory solid tumors.
V. Manax, Y. Wolf, G. Markel, L. Florin +11 more
2023Journal of Clinical Oncology0 citations Open access
Semantic Scholar
108 Unveiling the diversity in melanoma immunotherapy response biomarkers between lymph node and non-lymph node biopsies
E. Markovits, N. Asher, Guy Ben-Betzalel, A. Debby +13 more
2023Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar
Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.
Danielle K. DePalo, S. Naqvi, D. Ollila, T. Hieken +16 more
2023Journal of Clinical Oncology0 citations
Semantic Scholar
Better (a little) late than never: The impact of steroidal treatment initiation timing on the outcome of patients with melanoma treated with immunotherapy.
N. Asher, Neta Bar-Hai, Guy Ben-Betzalel, R. Stoff +3 more
2022Journal of Clinical Oncology0 citations
Semantic Scholar
The Survival-Inferred Fragility of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
D. Bomze, N. Asher, Omar Hasan Ali, L. Flatz +3 more
2020Social Science Research Network0 citations
Semantic Scholar
JS1.3 Autoimmune encephalitis as immune related adverse event (irAE) of check point inhibitors (CPI) not so rare as we thought
A. Taliansky, M. Gadot, D. Urban, J. Bar +5 more
2019Neuro-Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Guy Ben-Betzalel×25
Invite
Guy Ben-Betzalel — researcher profile on SciRah
R. Shapira-Frommer×25
Invite
R. Shapira-Frommer — researcher profile on SciRah
J. Schachter×22
Invite
J. Schachter — researcher profile on SciRah
G. Markel×18
Invite
G. Markel — researcher profile on SciRah

×16

Invite

S. Grynberg — researcher profile on SciRah

Invite

R. Stoff — researcher profile on SciRah

Yael Steinberg-Silman×8

Invite

Yael Steinberg-Silman — researcher profile on SciRah

Tomer Meirson×7

Invite

Tomer Meirson — researcher profile on SciRah

Invite

E. Baruch — researcher profile on SciRah

Invite

A. Debby — researcher profile on SciRah

Invite

I. Barshack — researcher profile on SciRah

Invite

B. Boursi — researcher profile on SciRah